Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Common matrix metalloproteinase 2 gene haplotypes may modulate left ventricular remodelling in hypertensive patients

Journal of Human Hypertension volume 26, pages 171–177 (2012)Cite this article

Abstract

Matrix metalloproteinases (MMPs) are involved in cardiac remodelling. We examined whether MMP-2 genetic polymorphisms are associated with hypertension and left ventricular (LV) remodelling in hypertensive patients. We studied 160 hypertensive patients and 123 healthy controls. Echocardiography was performed in all patients and the C−1306T (rs243865) and C−735T (rs 2285053) MMP-2 polymorphisms were analysed. Haplo.stats analysis was used to evaluate whether MMP-2 haplotypes are associated with hypertension and with extremes in LV mass index (LVMI). Multiple linear regression analysis was performed to assess whether MMP-2 genotypes or haplotypes affect LVMI and other echocardiography parameters. The C−1306T ‘CC’ genotype was associated with reduced LVMI and LV end-diastolic diameter (EDD) (P=0.0365 and P=0.0438, respectively). The haplotype ‘C, C’ was associated with reduced LVMI and EDD (P=0.0278 and P=0.0322, respectively). The comparison of upper and lower extremes of the LVMI phenotype showed that the ‘C, C’ haplotype was more common in the lower LVMI group (P=0.0060), whereas the ‘T, C’ haplotype was more common in the higher quartile of LVMI (P=0.0187), and this haplotype was associated with increased risk of higher LVMI values (odds ratio=3.5121, 95% confidence interval=1.3193–9.3494). The findings suggest that MMP-2 polymorphisms affect hypertension-induced LV remodelling.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Frey N, Olson EN . Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003; 65: 45–79.

    Article  CAS  Google Scholar 

  2. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP . Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561–1566.

    Article  CAS  Google Scholar 

  3. Fielitz J, Leuschner M, Zurbrugg HR, Hannack B, Pregla R, Hetzer R et al. Regulation of matrix metalloproteinases and their inhibitors in the left ventricular myocardium of patients with aortic stenosis. J Mol Med 2004; 82: 809–820.

    Article  CAS  Google Scholar 

  4. Givvimani S, Tyagi N, Sen U, Mishra PK, Qipshidze N, Munjal C et al. MMP-2/TIMP-2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure. Arch Physiol Biochem 2010; 116: 63–72.

    Article  CAS  Google Scholar 

  5. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006; 113: 2089–2096.

    Article  CAS  Google Scholar 

  6. Janicki JS, Brower GL, Gardner JD, Chancey AL, Stewart Jr JA . The dynamic interaction between matrix metalloproteinase activity and adverse myocardial remodeling. Heart Fail Rev 2004; 9: 33–42.

    Article  CAS  Google Scholar 

  7. Polyakova V, Hein S, Kostin S, Ziegelhoeffer T, Schaper J . Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. J Am Coll Cardiol 2004; 44: 1609–1618.

    Article  CAS  Google Scholar 

  8. Rizzi E, Castro MM, Prado CM, Silva CA, Fazan Jr R, Rossi MA et al. Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension. J Card Fail 2010; 16: 599–608.

    Article  CAS  Google Scholar 

  9. Spinale FG . Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007; 87: 1285–1342.

    Article  CAS  Google Scholar 

  10. Manso H, Krug T, Sobral J, Albergaria I, Gaspar G, Ferro JM et al. Variants of the Matrix Metalloproteinase-2 but not the Matrix Metalloproteinase-9 genes significantly influence functional outcome after stroke. BMC Med Genet 2010; 11: 40.

    Article  Google Scholar 

  11. Singh R, Srivastava P, Srivastava A, Mittal RD . Matrix metalloproteinase (MMP-9 and MMP-2) gene polymorphisms influence allograft survival in renal transplant recipients. Nephrol Dial Transplant 2010; 25: 3393–3401.

    Article  CAS  Google Scholar 

  12. Yu C, Zhou Y, Miao X, Xiong P, Tan W, Lin D . Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 2004; 64: 7622–7628.

    Article  CAS  Google Scholar 

  13. Price SJ, Greaves DR, Watkins H . Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 2001; 276: 7549–7558.

    Article  CAS  Google Scholar 

  14. Langers AM, Sier CF, Hawinkels LJ, Kubben FJ, van Duijn W, van der Reijden JJ et al. MMP-2 geno-phenotype is prognostic for colorectal cancer survival, whereas MMP-9 is not. Br J Cancer 2008; 98: 1820–1823.

    Article  CAS  Google Scholar 

  15. Pannu H, Kim DH, Guo D, King TM, Van Ginhoven G, Chin T et al. The role of MMP-2 and MMP-9 polymorphisms in sporadic intracranial aneurysms. J Neurosurg 2006; 105: 418–423.

    Article  CAS  Google Scholar 

  16. Mizon-Gerard F, de Groote P, Lamblin N, Hermant X, Dallongeville J, Amouyel P et al. Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the aetiology of left ventricular systolic dysfunction. Eur Heart J 2004; 25: 688–693.

    Article  CAS  Google Scholar 

  17. Gai X, Zhang Z, Liang Y, Chen Z, Yang X, Hou J et al. MMP-2 and TIMP-2 gene polymorphisms and susceptibility to atrial fibrillation in Chinese Han patients with hypertensive heart disease. Clin Chim Acta 2010; 411: 719–724.

    Article  CAS  Google Scholar 

  18. Bauters C, Lamblin N, Ennezat PV, Mycinski C, Tricot O, Nugue O et al. A prospective evaluation of left ventricular remodeling after inaugural anterior myocardial infarction as a function of gene polymorphisms in the renin-angiotensin-aldosterone, adrenergic, and metalloproteinase systems. Am Heart J 2007; 153: 641–648.

    Article  CAS  Google Scholar 

  19. Powell JT . Genes predisposing to rapid aneurysm growth. Ann N Y Acad Sci 2006; 1085: 236–241.

    Article  CAS  Google Scholar 

  20. Sales ML, Ferreira MC, Leme Jr CA, Velloso LA, Gallani MC, Colombo RC et al. Non-effect of p22-phox -930A/G polymorphism on end-organ damage in Brazilian hypertensive patients. J Hum Hypertens 2007; 21: 504–506.

    Article  CAS  Google Scholar 

  21. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7: 79–108.

    Article  Google Scholar 

  22. Lauer MS, Anderson KM, Larson MG, Levy D . A new method for indexing left ventricular mass for differences in body size. Am J Cardiol 1994; 74: 487–491.

    Article  CAS  Google Scholar 

  23. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA . Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70: 425–434.

    Article  Google Scholar 

  24. Castro MM, Rizzi E, Figueiredo-Lopes L, Fernandes K, Bendhack LM, Pitol DL et al. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 2008; 198: 320–331.

    Article  CAS  Google Scholar 

  25. Castro MM, Rizzi E, Prado CM, Rossi MA, Tanus-Santos JE, Gerlach RF . Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. Matrix Biol 2010; 29: 194–201.

    Article  CAS  Google Scholar 

  26. Castro MM, Rizzi E, Rodrigues GJ, Ceron CS, Bendhack LM, Gerlach RF et al. Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension. Free Radic Biol Med 2009; 46: 1298–1307.

    Article  CAS  Google Scholar 

  27. Martinez ML, Castro MM, Rizzi E, Fernandes K, Demacq C, Bendhack LM et al. Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats. Eur J Pharmacol 2008; 591: 224–230.

    Article  CAS  Google Scholar 

  28. Altieri P, Brunelli C, Garibaldi S, Nicolino A, Ubaldi S, Spallarossa P et al. Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur J Clin Invest 2003; 33: 648–656.

    Article  CAS  Google Scholar 

  29. Kandasamy AD, Chow AK, Ali MA, Schulz R . Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc Res 2010; 85: 413–423.

    Article  CAS  Google Scholar 

  30. Matsusaka H, Ide T, Matsushima S, Ikeuchi M, Kubota T, Sunagawa K et al. Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension 2006; 47: 711–717.

    Article  CAS  Google Scholar 

  31. Murphy G, Nagase H . Progress in matrix metalloproteinase research. Mol Aspects Med 2008; 29: 290–308.

    Article  CAS  Google Scholar 

  32. Lacchini R, Jacob-Ferreira AL, Luizon MR, Coeli FB, Izidoro-Toledo TC, Gasparini S et al. Matrix metalloproteinase 9 gene haplotypes affect left ventricular hypertrophy in hypertensive patients. Clin Chim Acta 2010; 411: 1940–1944.

    Article  CAS  Google Scholar 

  33. Roldan V, Marin F, Gimeno JR, Ruiz-Espejo F, Gonzalez J, Feliu E et al. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. Am Heart J 2008; 156: 85–91.

    Article  CAS  Google Scholar 

  34. Schulz R . Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol 2007; 47: 211–242.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo, Conselho Nacional de Desenvolvimento Científico e Tecnológico and Coordenadoria de Aperfeiçoamento de Pessoal de Nível Superior.

Author information

Authors and Affiliations

  1. Department of Pharmacology, Faculty of Medical Sciences, State University of Campinas, Campinas, Brazil

    R Lacchini & A L B Jacob-Ferreira

  2. Department of Pharmacology, Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil

    M R Luizon & J E Tanus-Santos

  3. Department of Internal Medicine, Faculty of Medical Sciences, State University of Campinas, Campinas, Brazil

    S Gasparini, M C S Ferreira-Sae, R Schreiber & W Nadruz Jr

Authors
  1. R Lacchini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A L B Jacob-Ferreira
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M R Luizon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Gasparini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M C S Ferreira-Sae
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Schreiber
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. W Nadruz Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J E Tanus-Santos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J E Tanus-Santos.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lacchini, R., Jacob-Ferreira, A., Luizon, M. et al. Common matrix metalloproteinase 2 gene haplotypes may modulate left ventricular remodelling in hypertensive patients. J Hum Hypertens 26, 171–177 (2012). https://doi.org/10.1038/jhh.2011.8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jhh.2011.8

Keywords

This article is cited by

Search

Advanced search

Quick links